Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 1145-1154

  Ling, Yi He ^a   Liebes, Leonard ^b   Jiang, Jian Dong ^c   Holland, James F ^c   Elliott, Peter J ^d   Adams, Julian ^d   Muggia, Franco M ^b   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 3; CYCLIN A; CYCLIN A KINASE; CYCLIN B; CYCLIN B KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOTRANSFERASE; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STABILITY;

APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROTUBULES; MITOSIS; MULTIENZYME COMPLEXES; MUTATION; PRECIPITIN TESTS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0037342895     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hochstrasser, M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol., 7: 215-223, 1995.
2. Juntsch, S., and Schlenker, S. Selective protein degradation: a journey's end within the proteasome. Cell, 82: 881-884, 1995.
3. Hershko, A. and Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 67: 425-480, 1998.
4. Desai, S. D. Liu, L. F., Vazquez-Abaad, D., and D'Arpa, P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272: 24159-24164, 1997.
5. Ciechanover, A., DiGiuseppe, A. J., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., and Brodeur, G. M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. USA, 88: 139-143, 1991.
6. Treier, M., Staszewski, L. M., and Bohmann, D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the δ domain. Cell, 78: 787-798, 1994.
7. Grimm, L. M., Gildberg, A. L., Porier, G. G., Schwartz, L. M., and Osborne, B. A. Proteasomes play an essential role in thymocyte apoptosis. EMBO J., 15: 3835-3844, 1996.
8. Drexler, H. C., Risau, W., and Konerding, M. A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J., 14: 65-77, 2000.
9. Adams, J., Behnke, M., Chen, S., Cruickdhank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y-T., Plamondon, L., and Stein, R. L. Potent and selective inhibitors of the proteasome: dipepidyl boronic acids. Bioorg. Med. Chem. Lett., 8: 333-338, 1998.
10. Adams, J., Palombella, V. J., Sausville, E. A., Jonson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliot, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999.
11. Ling, Y. H., Priebe, W., Yang, L-Y., Burke, T. G., Pommier, Y., and Perez-Soler, R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res., 53: 1583-1589, 1993.
12. Jiang, J-D., Davis, A. S., Middleton, K., Ling, Y. H., Perez-Soler, R., Holland, J. F., and Bekesi, J. G. 3-(Iodoacetmido)-bezoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res., 58: 5389-5395, 1998.
13. Koepp, D. M., Harper, J. W., and Elledge, S. J. How the cyclin became a cyclin: regulated proteolysis in the cycle. Cell, 97: 431-434, 1999.
14. Oren, M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem., 274: 36031-36043, 1999.
15. Cox, L. S., and Lane, D. P. Tumour suppressors, kinase and clamps: how p53 regulates the cell cycle. BioEssays, 17: 501-508, 1995.
16. Grisham, M. B., Palombella, V. J., Elliott, P., Conner, E. M., Brand, S., Wong, H. L., Pien, C., Mazzola, L. M., Destree, A., Parent, L., and Adams, J. Inhibition of NF-κB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol., 300: 345-363, 1999.
17. Glotzer, M., Murray, A. W., and Kirschner, M. W. Cyclin is degradation by the ubiquitin pathway. Nature (Lond.), 349: 132-138, 1991.
18. Sherwood, S. W., Kung, A. L., Roitelman, J., Simoni, R. D., and Schimke, R. T. In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteines protease inhibitor N-acetylleucylnorleucinal. Proc. Natl. Acad. Sci. USA, 90: 3353-3357, 1993.
19. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
20. Wu, X., and Levine, A. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
21. Lopes, U. G., Erhardt, P., Yao, R., and Cooper, G. M. P53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 272: 12893-12896, 1997.
22. Shinohara, K., Tomioka, M., Nakan, H., Tone, S., Ito, H., and Kawashim, S. Apoptosis induction resulting from proteasome inhibition. Biochem. J., 317: 385-388, 1996.
23. Cheng, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. Mdm2 and Bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ., 9: 79-84, 1998.
24. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chemova, O. B., and Stark, G. R. The p53 network. J. Biol. Chem., 273: 1-4, 1998.
25. Mocleod, K. F., Sherry, N., Hannon, G., Beech, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
26. Michieli, P., Chedid, M., Lin, D., Peirce, J. H., Mecer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
27. WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia (Baltimore), 14: 1276-1283, 2000.
28. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
29. 2 arrest in hepatocytes and a reduction in liver binuclation: the role of p53 and p21. FASEB J., 14: 1073-1082, 2000.
30. 2 phase of the cell cycle. J. Biol. Chem., 275: 23181-23186, 2000.
31. Guadagno, T. M., and Newport, J. W. Cdk2 kinase is required for entry into mitosis as a positive regulator of cdc2-cyclin B kinase activity. Cell, 84: 73-82, 1996.
32. Cis-1/Waf-1 deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood, 93: 1390-1398, 1999.
33. 2/M arrest after DNA damage. J. Biol. Chem., 276: 42971-42977, 2001.
34. King, K. L., and Cidlowski, J. A. Cell cycle and apoptosis: common pathways to life and death. J. Cell. Biochem., 58: 175-180, 1995.
35. 2-M arrest: evidence of commitment to apoptosis rather than mitotic death. Clin. Cancer Res., 6: 3756-3765, 2000.
36. 2 delay potentiates cell death by apoptosis and/or induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin. Cancer Res., 3: 1371-1378, 1997.